64.11% of the stock is currently owned by hedge funds and other institutional investors. now owns 81 shares of the medical research company’s stock worth $39,000 after purchasing an additional 47 shares during the period. boosted its holdings in shares of Bio-Rad Laboratories by 138.2% during the first quarter. Toroso Investments LLC now owns 1,952 shares of the medical research company’s stock valued at $935,000 after acquiring an additional 586 shares during the last quarter. Toroso Investments LLC raised its stake in shares of Bio-Rad Laboratories by 42.9% during the first quarter. Brandywine Global Investment Management LLC bought a new stake in Bio-Rad Laboratories in the 1st quarter worth $7,546,000.
ProShare Advisors LLC now owns 3,402 shares of the medical research company’s stock valued at $1,630,000 after buying an additional 493 shares during the period. ProShare Advisors LLC boosted its position in Bio-Rad Laboratories by 16.9% during the 1st quarter. Prelude Capital Management LLC now owns 14,516 shares of the medical research company’s stock valued at $6,953,000 after purchasing an additional 486 shares during the period. Prelude Capital Management LLC boosted its stake in shares of Bio-Rad Laboratories by 3.5% during the first quarter. Institutional investors have recently added to or reduced their stakes in the business. Institutional Trading of Bio-Rad Laboratories The company has a current ratio of 5.56, a quick ratio of 4.28 and a debt-to-equity ratio of 0.12. The company’s fifty day moving average price is $397.91 and its two-hundred day moving average price is $436.50. The company has a market cap of $10.83 billion, a price-to-earnings ratio of -55.93 and a beta of 0.91. Bio-Rad Laboratories has a 1-year low of $344.63 and a 1-year high of $572.70. Bio-Rad Laboratories Stock PerformanceīIO opened at $365.80 on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus price target of $627.25. They issued an “overweight” rating and a $550.00 target price for the company. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Friday, June 16th. They issued a “buy” rating for the company. began coverage on Bio-Rad Laboratories in a research report on Thursday, May 18th. A number of other research firms have also commented on BIO.
0 kommentar(er)
